An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

Conditions:   Retinitis Pigmentosa;   Usher Syndrome Type 2 Intervention:   Drug: RNA antisense oligonucleotide for intravitreal injection Sponsor:   ProQR Therapeutics Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials